摘要:
The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A′, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.
摘要:
The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A′, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.
摘要:
The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetra-cyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
摘要:
The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
摘要:
The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.
摘要:
The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.
摘要:
Embodiments of the present invention provide a method and a media gateway for realizing a packet-packet model session. According to an embodiment of the present invention, the media gateway determines whether the session meets the TrFO protocol. In the case that the session doesn't meet the TrFO protocol, the media gateway inserts a pair of back-to-back TCs, activates the pair of back-to-back TCs such that the pair of back-to-back TCs perform the TFO negotiation, thus making the pair of back-to-back TCs work in a pass-through mode. In the embodiments of the present invention, because it is possible to bypass the codec ability of the pair of back-to-back TCs, the voice quality deterioration introduced in the prior art due to adopting the codec conversion may be avoided.
摘要:
A method and code for controlling the operation of a deactivatable valve lifter of an internal combustion engine includes determining an oil viscosity measure based upon an engine oil pressure achieved when the engine is operating at a warm engine idle operating condition; determining a minimum oil temperature for actuator operation based on a comparison of the oil viscosity measure with a stored value representing the oil's nominal viscosity; and enabling actuator operation when an instantaneous oil temperature is not less than the minimum oil temperature.
摘要:
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
摘要:
A method and code for controlling the operation of a deactivatable valve lifter of an internal combustion engine includes determining an oil viscosity measure based upon an engine oil pressure achieved when the engine is operating at a warm engine idle operating condition; determining a minimum oil temperature for actuator operation based on a comparison of the oil viscosity measure with a stored value representing the oil's nominal viscosity; and enabling actuator operation when an instantaneous oil temperature is not less than the minimum oil temperature.